Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.42 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16993031 | 0.92 | NR1H2 (0.41) | NR1H2GPR119SETD7USP2 | |
| SCHEMBL20211587 | 0.92 | NR1H2 (0.41) | NR1H2GPR119SETD7USP2 | |
| SCHEMBL17910113 | 0.92 | NR1H2 (0.41) | NR1H2GPR119SETD7USP2 | |
| SCHEMBL1087572 | 0.83 | NR1H2 (0.47) | NR1H2GPR119SETD7USP2SMN1; SMN2 | |
| SCHEMBL16993261 | 0.82 | NR1H2 (0.50) | NR1H2GPR119USP2SMN1; SMN2 | |
| SCHEMBL16993263 | 0.82 | NR1H2 (0.50) | NR1H2GPR119USP2SMN1; SMN2 | |
| SCHEMBL30778427 | 0.81 | NR1H2 (0.44) | NR1H2GPR119SETD7USP2SMN1; SMN2 | |
| SCHEMBL334402 | 0.80 | NR1H2 (0.53) | NR1H2GPR119SETD7USP2SMN1; SMN2 | |
| SCHEMBL10220898 | 0.80 | NR1H2 (0.53) | NR1H2GPR119SETD7USP2SMN1; SMN2 | |
| SCHEMBL10264379 | 0.80 | NR1H2 (0.49) | NR1H2GPR119SETD7USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630414-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121256-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |